Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A clinical breakdown of the legal status of compounded Adderall XR (mixed amphetamine salts), including FDA shortage declarations, 503A/503B pharmacy rules, DEA scheduling, and what the end of the shortage means for patients.
Read clinical reviewA detailed review of Adderall XR (mixed amphetamine salts) safety signals in the FDA Adverse Event Reporting System (FAERS), including cardiovascular, psychiatric, and pediatric findings.
Read clinical reviewA complete timeline of Adderall XR FDA approval, label revisions, boxed warnings, and post-market safety surveillance from 1996 through 2026.
Read clinical reviewA clinician-reviewed guide to Adderall XR (mixed amphetamine salts) regulatory status worldwide, covering FDA approval history, DEA scheduling, EMA classification, and current label safety information.
Read clinical reviewA complete timeline of Adderall XR (mixed amphetamine salts) FDA label changes from 2020 through 2026, covering cardiovascular warnings, shortage declarations, pregnancy data revisions, and abuse-deterrent language updates.
Read clinical reviewA clinical overview of the Adderall XR regulatory history, current pipeline competitors, and next-generation ADHD stimulant formulations under FDA review or in late-stage trials.
Read clinical reviewHow the FDA and EMA differ in their regulatory handling of Adderall XR (mixed amphetamine salts), including approval history, labeling, safety surveillance, and what European patients use instead.
Read clinical review